Randox Presents the World’s First Fully Automated, Random Access Biochip Testing Platform

25 Jul 2010
Sarah Sarah
Marketing / Sales

Randox has chosen AACC 2010 in Anaheim, California to present the Evidence Evolution, the latest addition to the Evidence family of immunoassay analysers.

The American Association for Clinical Chemistry (AACC) is the world’s largest clinical lab exposition, attracting a record number of over 20,000 attendees and 650 exhibitors this year, covering all areas of clinical diagnostics including automation, point of care, biotech plus much more. As a major sponsor and one of the largest exhibitors present, Randox will display their complete product range, from clinical chemistry analysers and reagents to quality control and life sciences.

The focus however, will be centred on the unveiling of the new Evidence Evolution. Pushing the boundaries of laboratory testing, the Evidence Evolution offers complete consolidation on one platform. Established and proven Biochip Array Technology provides limitless multiplex capabilities enabling simultaneous testing from a single small volume sample. Coupling such advanced technology with our industry leading test menu enables the Evidence Evolution to provide laboratories with unsurpassed patient profiling capabilities whilst saving time and costs.

Advanced performance, productivity and quality are key benefits of the Evidence Evolution. This is achieved through the integration of state of the art e-touch software, advanced precision bio-drive robotics and true random access capabilities. The system also hosts high quality and highly secure remote access diagnostics, ensuring advanced technical support is never more than a click away.

The official launch will take place on Tuesday 27th July at 10am at the Randox booth, # 6800.

Links

Tags